DLL3 Targeting CAR-T Cell Therapy Patent Granted to Allogene Therapeutics

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

The USPTO granted Patent US12606623B2 to Allogene Therapeutics, Inc. covering DLL3 binding agents and chimeric antigen receptors (CARs) for use in immune cell therapies, specifically CAR-T cells. The patent includes 26 claims and covers methods of making and using DLL3-specific CARs. This grant establishes exclusive IP rights for the assignee in the specified therapeutic domain.